RENAU.UNSP.ARD 1/5 EO-20

Research RENAU.UNSP.ARD 1/5 EO-20 (56S0) on Bullrun: valuation model: 20.6% overvalued, market cap EUR 15.27B, P/E 56.1, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker56S0
• ExchangeF
• CountryFrance
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyEUR
• Valuation signal20.6% overvalued
• Market capEUR 15.27B
• P/E56.1
• Dividend yield0.4%
• Financial periodQ1 2026
• RevenueEUR 761.50M
• Net incomeEUR 88.10M
• Free cash flowEUR 123.70M
• Gross margin45.4%

Valuation Snapshot

Bullrun's latest valuation model marks RENAU.UNSP.ARD 1/5 EO-20 as 20.6% overvalued; latest market cap is EUR 15.27B; P/E is 56.1; dividend yield is 0.4%.

About RENAU.UNSP.ARD 1/5 EO-20

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services;

Frequently asked questions

Is RENAU.UNSP.ARD 1/5 EO-20 overvalued or undervalued?

Bullrun's valuation model currently marks RENAU.UNSP.ARD 1/5 EO-20 as 20.6% overvalued.

What is RENAU.UNSP.ARD 1/5 EO-20's market cap?

RENAU.UNSP.ARD 1/5 EO-20's market capitalization is EUR 15.27B.

What is RENAU.UNSP.ARD 1/5 EO-20's P/E ratio?

RENAU.UNSP.ARD 1/5 EO-20's price-to-earnings (P/E) ratio is 56.1.

Does RENAU.UNSP.ARD 1/5 EO-20 pay a dividend?

RENAU.UNSP.ARD 1/5 EO-20 has a dividend yield of 0.4%.

What does RENAU.UNSP.ARD 1/5 EO-20 do?

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies;